AstraZeneca CEO Pascal Soriot Announces $700 Million Investment in New Drug Manufacturing Facilities in China

Global pharmaceutical giant AstraZeneca's CEO, Pascal Soriot, stated that the company has invested $700 million (approximately RMB 5.06 billion) and $475 million in building new drug manufacturing facilities in Qingdao and Wuxi, China, respectively. He expressed strong confidence in the company’s long-term development in China. (CGTN)Original Link